Patent Landmark Cases

Table of Contents
1. Indian Patent Landmark Cases
2. International Patent Landmark Cases
3. Comparative Table: Key Patent Doctrines Across Jurisdictions
4. Key Sections and Their Judicial Interpretation
5. Patent Infringement Doctrines and Tests
6. Patent Remedies - Judicial Approaches
7. Patent Opposition and Revocation - Key Principles
8. TRIPS Agreement and Patent Cases
9. Recent Trends and Emerging Issues
View more

Patent law is frequently tested through landmark judicial precedents that establish key principles. Understanding these cases is critical for identifying patentability criteria, exceptions, infringement standards, and remedies. This section covers the most important Indian and international patent cases that shape modern patent jurisprudence and are repeatedly referenced in legal examinations.

1. Indian Patent Landmark Cases

1.1 Novartis AG v. Union of India (2013) - Section 3(d) Interpretation

This Supreme Court case is the most significant Indian patent decision post-2005 Patent Act amendments.

• Facts: Novartis sought patent for Gleevec (Imatinib Mesylate), a cancer drug. The application was for the beta crystalline form of Imatinib Mesylate, a derivative of the known compound Imatinib.
• Issue: Whether the new form qualified for patent under Section 3(d) of the Patents Act, 1970.
• Section 3(d): States that mere discovery of a new form of a known substance is not patentable unless it differs significantly in properties with regard to efficacy.
• Judgment: Supreme Court rejected the patent. Held that Novartis failed to prove enhanced therapeutic efficacy over the known compound.
• Key Principle: Evergreening (obtaining new patents for minor modifications without significant improvement) is not permitted under Indian law.
• Efficacy Standard: For pharmaceutical patents, efficacy means therapeutic efficacy, not just improved bioavailability or physicochemical properties.
• Impact: Protects generic drug industry and public health by preventing frivolous patents on incremental modifications.

1.2 Bishwanath Prasad Radhey Shyam v. Hindustan Metal Industries (1979)

This Supreme Court decision established fundamental principles for patent validity in India.

• Facts: Patent dispute over a packing and sealing machine.
• Issue: What constitutes an invention under patent law?
• Three Essential Requirements Established:
  1. Novelty: The invention must be new and not published anywhere in the world before the date of filing.
  2. Inventive Step (Non-obviousness): The invention must not be obvious to a person skilled in the art.
  3. Utility (Industrial Application): The invention must be capable of industrial application.
• Key Principle: Mere workshop improvement or skilled craftsman's work does not qualify as invention.
• Inventive Step Test: Would a person reasonably skilled in the art find the solution obvious when faced with the same problem?
• Impact: This judgment codified the basic patentability criteria applied in all subsequent cases.

1.3 Dimminaco AG v. Controller of Patents (2002) - Delhi High Court

Important case on microbiological processes and pharmaceutical patents pre-2005 amendments.

• Facts: Patent application for a process to produce a pharmaceutical compound using microbiological methods.
• Issue: Whether processes involving microbiological methods are patentable under Section 3(j) exception.
• Section 3(j): Plants and animals (except microorganisms) and biological processes (except microbiological processes) are not patentable.
• Judgment: Delhi High Court held that microbiological processes are patentable as they constitute exceptions to the general bar on biological processes.
• Key Principle: Distinction between biological processes (non-patentable) and microbiological processes (patentable).
• Microbiological Process: Process involving microorganisms, including recombinant DNA technology, genetic engineering, and fermentation processes.

1.4 Monsanto Technology LLC v. Nuziveedu Seeds Ltd (2018) - Supreme Court

Critical case on patentability of plant varieties and scope of patent protection.

• Facts: Monsanto held patents for Bt Cotton technology (insect-resistant gene). Nuziveedu used this technology in seeds and disputed royalty payments.
• Issue: Whether plants and seeds containing patented genes are protected under patent law or only under the Protection of Plant Varieties and Farmers' Rights Act, 2001 (PPVFR Act).
• Judgment: Supreme Court held that Section 3(j) bars patents on plants and seeds, even if they contain patented genes. Patent protection is limited to the isolated gene, not the plant itself.
• Key Principle: PPVFR Act is the special law for plant variety protection; patent law cannot extend to plants.
• Impact: Limits scope of biotechnology patents in agriculture. Seeds cannot be claimed under patent law.

1.5 F. Hoffmann-La Roche Ltd v. Cipla Ltd (2008) - Delhi High Court

Landmark case on interim injunctions in patent infringement suits.

• Facts: Roche sought interim injunction against Cipla for manufacturing generic version of Erlotinib (Tarceva), an anti-cancer drug.
• Issue: Grounds for granting interim injunction in patent disputes.
• Three-Fold Test for Interim Injunction:
  1. Prima Facie Case: Patent holder must show a credible case of infringement.
  2. Balance of Convenience: Harm to patent holder if injunction denied vs. harm to defendant if granted.
  3. Irreparable Injury: Whether damages would be adequate remedy or injunction is necessary.
• Judgment: Delhi High Court refused injunction. Held that in pharmaceutical cases, public interest in accessing affordable medicines must be considered.
• Key Principle: Courts balance patent rights against public health concerns, especially for life-saving drugs.
• Impact: Generic manufacturers can continue production pending final judgment if strong public interest exists.

1.6 Electronic Corporation of India Ltd (ECIL) v. Commissioner of Patents (2015)

Important case clarifying computer-related inventions (CRI) under Section 3(k).

• Facts: ECIL's patent application for a method of finding location of mobile devices was rejected as "computer programme per se".
• Issue: What constitutes a "computer programme per se" that is non-patentable under Section 3(k)?
• Section 3(k): Mathematical or business methods, computer programmes per se, and algorithms are not patentable.
• Judgment: Intellectual Property Appellate Board (IPAB) held that if a computer programme produces a technical effect or solves a technical problem, it is patentable.
• Technical Effect Test: The invention must go beyond merely running software on a computer; it must have real-world technical application.
• Key Principle: Computer programmes with technical contribution are patentable; mere algorithms or business methods are not.

1.7 Bayer Corporation v. Union of India (2014) - Compulsory Licensing

First compulsory license granted in India post-TRIPS.

• Facts: Natco Pharma applied for compulsory license to manufacture Sorafenib Tosylate (Nexavar), a kidney cancer drug patented by Bayer.
• Issue: Grounds for granting compulsory license under Section 84 of Patents Act.
• Section 84 Grounds:
  1. Reasonable requirements of the public are not satisfied.
  2. Invention is not available to the public at reasonably affordable price.
  3. Invention is not worked in India (local manufacturing requirement).
• Controller's Decision: Granted compulsory license to Natco in 2012. Bayer's drug priced at ₹2,80,000 per month; Natco to sell at ₹8,800 per month. Natco to pay 6% royalty to Bayer.
• Bombay High Court (2014): Upheld compulsory license. Rejected Bayer's argument that only 2% of patients in India could afford their price; affordability must consider broader population.
• Key Principle: Affordability and accessibility are paramount considerations. Patent rights are not absolute; public health takes precedence.
• Impact: Demonstrates India's commitment to using TRIPS flexibilities for public health.

1.8 Biswanath Prasad v. Hindustan Metal Industries - Doctrine of Equivalents

Established principles for determining patent infringement.

• Doctrine of Equivalents: Infringement occurs even if accused product does not literally copy every element, if it performs substantially the same function in substantially the same way to achieve substantially the same result.
• Pith and Marrow Doctrine: Courts must identify the essential integers (pith and marrow) of the patent claim. If accused product takes the essential features, infringement exists.
• Three-Fold Test for Equivalents:
  1. Same function
  2. Same way/manner
  3. Same result
• Key Principle: Patent protection extends beyond literal wording to prevent easy circumvention through minor modifications.

2. International Patent Landmark Cases

2.1 Diamond v. Chakrabarty (1980) - US Supreme Court

Groundbreaking case on biotechnology patents and patentability of life forms.

• Facts: Ananda Chakrabarty genetically engineered a bacterium capable of breaking down crude oil, useful for cleaning oil spills.
• Issue: Whether a living, genetically modified organism is patentable subject matter.
• Judgment: US Supreme Court held that genetically modified microorganisms are patentable as they are products of human ingenuity, not nature's handiwork.
• Key Principle: "Anything under the sun made by man" is patentable subject matter, including living organisms if they are human-made.
• Impact: Opened floodgates for biotechnology patents globally. Established that modified living organisms differ from naturally occurring organisms.
• Distinction: Discovery of natural organism = non-patentable; Invention of modified organism = patentable.

2.2 Association for Molecular Pathology v. Myriad Genetics (2013) - US Supreme Court

Critical case on patentability of human genes.

• Facts: Myriad Genetics held patents on isolated BRCA1 and BRCA2 genes associated with breast and ovarian cancer risk.
• Issue: Are isolated human genes patentable?
• Judgment: US Supreme Court held that naturally occurring DNA sequences are products of nature and not patentable, even when isolated from the body.
• Exception: Complementary DNA (cDNA) is patentable because it is synthetically created and does not naturally occur.
• Key Principle: Mere isolation of natural product does not make it patentable invention. Human intervention must create something new.
• Impact: Limited gene patents; promoted genetic testing accessibility by removing monopolies on diagnostic tests.

2.3 State Street Bank & Trust Co. v. Signature Financial Group (1998) - US Federal Circuit

Controversial case on business method patents (later overturned).

• Facts: Patent for a computer system managing mutual fund investments using a specific algorithm.
• Issue: Are business methods patentable?
• Original Judgment (1998): Federal Circuit held that business methods are patentable if they produce a "useful, concrete, and tangible result".
• Impact: Led to explosion of business method and software patents in the US.
• Reversal: This approach was effectively overturned by Bilski v. Kappos (2010) and Alice Corp. v. CLS Bank (2014), which restricted business method patents.

2.4 Bilski v. Kappos (2010) - US Supreme Court

Established stricter standards for process patents and business methods.

• Facts: Patent application for a method of hedging risk in commodities trading.
• Issue: What is the test for patentability of business processes?
• Judgment: Supreme Court rejected the patent. Held that abstract ideas are not patentable merely because they are implemented on a computer or involve mathematical formulas.
• Machine-or-Transformation Test: A process is patentable if it is tied to a particular machine or transforms an article into a different state. This test is a useful clue but not the sole test.
• Key Principle: Abstract ideas, even if implemented on computer, are not patentable unless they involve significant additional elements.

2.5 Alice Corporation v. CLS Bank International (2014) - US Supreme Court

Further restricted software and business method patents.

• Facts: Patents for computer-implemented system for mitigating settlement risk in financial transactions.
• Issue: Are computer-implemented abstract ideas patentable?
• Two-Step Test Established:
  1. Determine if claim is directed to an abstract idea, law of nature, or natural phenomenon.
  2. If yes, examine whether additional elements transform the claim into a patent-eligible application (i.e., something significantly more than the abstract idea itself).
• Judgment: Patents invalid. Merely implementing abstract idea on generic computer does not make it patentable.
• Key Principle: "Inventive Concept" must exist beyond the abstract idea. Generic computer implementation is insufficient.
• Impact: Significantly reduced software and business method patents in US. Many existing patents invalidated.

2.6 KSR International Co. v. Teleflex Inc. (2007) - US Supreme Court

Important case on non-obviousness (inventive step) standard.

• Facts: Patent dispute over adjustable automobile pedal system.
• Issue: What is the proper standard for determining obviousness?
• Teaching-Suggestion-Motivation (TSM) Test: Federal Circuit previously required explicit teaching, suggestion, or motivation in prior art to combine references.
• Judgment: Supreme Court rejected rigid TSM test. Held that obviousness analysis must consider whether skilled artisan would have been motivated to combine prior art elements by common sense and ordinary innovation.
• Expanded Obviousness Grounds:
  • Market demands or design incentives
  • Obvious to try approaches
  • Common sense of person skilled in art
• Key Principle: Inventive step cannot be established merely because no explicit teaching to combine prior art exists. Common sense and predictable results make combinations obvious.
• Impact: Made it easier to challenge patents on obviousness grounds; raised bar for patentability.

2.7 eBay Inc. v. MercExchange, L.L.C. (2006) - US Supreme Court

Changed standards for granting permanent injunctions in patent cases.

• Facts: MercExchange sued eBay for patent infringement. Lower court denied permanent injunction despite finding infringement.
• Issue: Is permanent injunction automatic remedy upon finding patent infringement?
• Judgment: Supreme Court held that permanent injunction is not automatic. Courts must apply traditional four-factor equitable test:
• Four-Factor Test for Injunction:
  1. Plaintiff suffered irreparable injury
  2. Monetary damages are inadequate remedy
  3. Balance of hardships favors injunction
  4. Public interest would not be disserved
• Key Principle: Patent rights do not automatically entitle holder to injunction. Courts must weigh equities.
• Impact: Reduced power of patent trolls (non-practicing entities) who relied on injunction threats for licensing revenue.

2.8 Windsurfing International Inc. v. Tabur Marine (1985) - UK Case

Established systematic approach to assess inventive step.

• Four-Step Windsurfing Test:
  1. Identify the inventive concept of the claim.
  2. Identify what was common general knowledge to person skilled in art at priority date.
  3. Identify the differences between prior art and claimed invention.
  4. Assess whether those differences constitute an obvious step or require inventive ingenuity.
• Key Principle: Provides structured framework for inventive step analysis, widely adopted in Commonwealth jurisdictions including India.

3. Comparative Table: Key Patent Doctrines Across Jurisdictions

4. Key Sections and Their Judicial Interpretation

4.1 Section 3 - What Are Not Inventions (India)

• Section 3(a): Inventions frivolous or contrary to natural laws - not patentable.
• Section 3(b): Inventions contrary to public order, morality, or health - excluded.
• Section 3(c): Mere discovery of scientific principle or abstract theory - not patentable.
• Section 3(d): New form of known substance without enhanced efficacy - not patentable (Novartis case).
• Section 3(h): Methods of agriculture or horticulture - excluded.
• Section 3(i): Medical treatment methods, diagnostic methods - not patentable (but pharmaceutical products are).
• Section 3(j): Plants, animals (except microorganisms), biological processes (except microbiological) - excluded (Monsanto case).
• Section 3(k): Mathematical methods, business methods, computer programmes per se, algorithms - not patentable (ECIL case).
• Section 3(m): Traditional knowledge - not patentable.
• Section 3(p): Inventions that are traditional knowledge or aggregation/duplication of known properties - excluded.

4.2 Section 84 - Compulsory Licenses (India)

• Grounds: Reasonable public requirements not met; not available at affordable price; not worked in India.
• Time Limit: Can be applied 3 years after patent grant.
• Judicial Interpretation: Bayer case clarified that affordability must consider broader Indian population, not just purchasing capacity of wealthy segment.
• Royalty: Compulsory licensee must pay reasonable royalty to patentee (determined case-by-case).

4.3 Section 8 - Information and Undertaking (India)

• Requirement: Applicant must disclose foreign patent applications for same or substantially same invention.
• Purpose: Prevents applicants from obtaining patents in India that were rejected abroad for lack of novelty/inventive step.
• Failure Consequences: Non-compliance can lead to patent refusal or revocation.

5. Patent Infringement Doctrines and Tests

5.1 Doctrine of Equivalents

Prevents infringers from making insubstantial changes to avoid literal infringement.

• Triple Identity Test: Same function + same way + same result = infringement.
• Application: Accused product need not copy every element literally if it achieves same objective through equivalent means.
• Limitation: Cannot extend beyond prior art (cannot claim equivalents that would cover prior art).

5.2 Pith and Marrow Doctrine

Focuses on the essential features of patented invention.

• Test: Does accused product take the essential integers (pith and marrow) of the patent?
• Difference from Literal Infringement: Looks beyond exact wording to substance of invention.
• Application: Courts identify core inventive concept and assess whether accused product appropriates it.

5.3 Reverse Doctrine of Equivalents

Rare defense where accused product, though literally falling within claim scope, is so different in principle that no infringement exists.

• Rationale: Prevents overbroad patent claims from stifling genuine innovation.
• Application: Seldom successful; requires showing substantially different working principle.

6. Patent Remedies - Judicial Approaches

6.1 Injunctions

• Interim Injunction: Granted during pendency of suit if plaintiff establishes prima facie case, balance of convenience, and irreparable injury.
• Permanent Injunction: Granted after full trial if infringement proven. Not automatic (eBay principle adopted in India).
• Public Interest Exception: Courts deny injunction if public health significantly affected (Roche v. Cipla approach).

6.2 Damages and Accounts of Profits

• Reasonable Royalty: Minimum damages equal to hypothetical licensing fee.
• Lost Profits: Actual losses suffered by patentee due to infringement.
• Accounts of Profits: Disgorgement of infringer's gains from infringing sales.
• Election: Patentee must elect between damages and accounts of profits (cannot claim both).

6.3 Anton Piller Orders (Search and Seizure)

• Purpose: Prevent destruction of evidence by infringer.
• Conditions: Strong prima facie case; serious potential damage; clear evidence that defendant possesses incriminating documents/materials; real possibility of destruction.
• Procedure: Ex parte order allowing plaintiff to enter defendant's premises and seize infringing goods and documents.

7. Patent Opposition and Revocation - Key Principles

7.1 Pre-Grant Opposition (Section 25(1))

• Timing: After publication of application but before grant.
• Who Can File: Any person can file pre-grant opposition.
• Grounds: Same as Section 25(2) - lack of novelty, obviousness, non-disclosure, etc.

7.2 Post-Grant Opposition (Section 25(2))

• Timing: Within 12 months of patent grant.
• Who Can File: Any interested person.
• Grounds Include:
  1. Wrongful obtaining
  2. Not patentable under Section 3 or 4
  3. Lack of novelty/inventive step
  4. Non-disclosure of foreign applications (Section 8)
  5. Insufficient disclosure (not enabling)

7.3 Revocation (Section 64)

• Forum: Can be sought from High Court or Appellate Board.
• Timing: Any time during patent term.
• Grounds: Similar to post-grant opposition grounds, plus non-working of patent.
• Effect: Patent treated as never having been granted (retrospective nullification).

8. TRIPS Agreement and Patent Cases

8.1 TRIPS Flexibilities for Public Health

• Doha Declaration (2001): Affirmed that TRIPS Agreement should be interpreted to support public health, allowing countries to use flexibilities like compulsory licensing.
• Article 27: Patents available for inventions in all fields of technology, but subject to certain exceptions.
• Article 30: Limited exceptions to patent rights allowed (research exception, prior user rights).
• Article 31: Permits compulsory licensing under certain conditions, including national emergency and public non-commercial use.
• Indian Implementation: Section 3(d) and compulsory licensing provisions (Section 84-92) utilize TRIPS flexibilities.

8.2 Mailbox Applications (Pre-2005)

• Background: India introduced product patents in pharmaceuticals from January 1, 2005 (TRIPS deadline).
• Mailbox Provision: Applications filed between 1995-2005 were kept in "mailbox" and examined after 2005.
• Exclusive Marketing Rights (EMR): During transitional period, applicants could get EMR for 5 years if they obtained patent in another country.
• Novartis Case Context: Gleevec application was mailbox application filed in 1998, examined post-2005 under amended Act.

9. Recent Trends and Emerging Issues

9.1 Standard Essential Patents (SEPs)

• Definition: Patents essential to comply with technical standards (e.g., telecommunication standards).
• FRAND Commitment: SEP holders must license on Fair, Reasonable, and Non-Discriminatory (FRAND) terms.
• Key Issue: Determining FRAND royalty rates; whether injunctions should be granted for SEP infringement.
• Ericsson v. Intex (2015): Delhi High Court granted injunction for SEP infringement when implementer not willing licensee.

9.2 Patent Linkage

• Concept: Linking drug regulatory approval to patent status (used in US and some countries).
• Indian Position: India does not have patent linkage system. Drug Controller can approve generics even if patents exist; patent disputes resolved separately in courts.
• Advantage: Promotes generic entry and affordability; patent holder must enforce rights through infringement suits.

9.3 Artificial Intelligence and Patents

• Inventorship Issue: Can AI be named as inventor? Most jurisdictions (including India) require human inventor.
• AI-Generated Inventions: Patentable if human contribution exists in training, selecting output, or applying AI.
• DABUS Case (Various Jurisdictions): Applications naming AI system "DABUS" as inventor rejected globally; only South Africa granted patent.

9.4 Traditional Knowledge Protection

• Section 3(p): Bars patents on traditional knowledge or its mere aggregation.
• Traditional Knowledge Digital Library (TKDL): Database of Indian traditional knowledge in patent-searchable format to prevent biopiracy.
• Success: Several foreign patent applications (turmeric, neem, basmati) successfully challenged using TKDL evidence.

Mastering these landmark cases provides essential foundation for patent law analysis in competitive examinations. Focus on the facts, issues, legal principles established, and their practical impact for each case. Understanding the ratio decidendi (reasoning) behind judgments enables application to hypothetical scenarios. Pay special attention to Indian cases interpreting Sections 3(d), 3(j), 3(k), and Section 84, as these represent unique features of Indian patent law frequently tested in exams. International cases demonstrate comparative approaches and influence Indian judicial thinking, particularly in emerging technology areas.